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maintain the mature chondrocyte phenotype avoiding terminal differentia-
tion towards hypertrophy represents a major issue and is the objective of
this study.
Methods: Bone marrow-derived murine MSCs were induced to differentiate
towards chondrocytes using the micropellet culture technique in presence
of Wnt-6 containing conditioned medium (CM). CM was obtained after
incubation of a chondrogenic medium consisting of DMEM supplemented
with ITS, proline, ascorbic acid and sodium pyruvate for 48h on conﬂuent
NIH-3T3 cells stably transfected to secrete Wnt-6. As controls, CM from
NIH-3T3 cells or BMP-2 containing medium was used. Similar conditions
were used to obtain CM with osteogenic or adipogenic media. After 21 days,
quantitative RT-PCR was performed on total RNA to detect the expression
of markers speciﬁc for each lineage and staining speciﬁc for proteoglycans,
mineralization or lipid droplets was performed. Western blotting with anti-
β-catenin, anti-JNK or anti-PKC antibodies was performed after migration
and transfer on nitrocellulose membranes of 20 μg total proteins extracted
from pellets after a time course exposure to the different CM.
Results: Pellet culture of murine MSCs in presence of NIH-derived CM or
chondrogenic medium alone did not up-regulate the chondrocytic markers.
On the contrary, Wnt-6 containing CM was suﬃcient to induce the differ-
entiation of MSCs into chondrocytes as shown by the induction of collagen
type IIB, aggrecan and COMP and a positive staining for proteoglycans.
The expression levels of the transcripts were lower than those induced by
BMP-2. However, contrary to BMP-2, we observed the lack of induction of
the hypertrophic markers collagen type X and alkaline phosphatase when
MSCs were cultured in Wnt-6 CM. Interestingly, in osteogenic or adipogenic
conditions, MSCs did not up-regulate the markers speciﬁc for osteoblasts or
adipocytes and rather decreased their expression level. The up-regulation
of chondrocytic markers by Wnt-6 was associated with a lack of induction
of the β-catenin or JNK pathways and preliminary results suggest that PKC
signalling may be induced.
Conclusions: Our results suggest that Wnt-6 is one new chondrogenic
factor suﬃcient to speciﬁcally induce the generation of chondrocytes
and inhibiting their terminal differentiation. Preliminary results suggest
that Wnt-6 might induce the PKC-dependent pathway to activate the
chondrocyte-speciﬁc genes.
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Purpose: Human bone marrow stromal cells (hBMSCs) are experimentally
being used in patients as a cell-based therapy for cartilage repair. To verify
the safety and eﬃcacy of such approaches it is necessary to determine the
fate of these implanted cells. Cell labeling using superparamagnetic iron
oxides (SPIOs) enables non-invasive in vivo cell tracking by MRI, and has
already been used in a clinical setting in various ﬁelds. In this study we de-
scribe a major step towards application of SPIO-labeling for cell tracking in
clinical cell-based cartilage repair approaches. We investigated the safety,
intra-articular MRI traceability and the possibility of SPIO re-uptake of this
cell tracking technique.
Methods: Safety: hBMSCs from three donors were labeled in triplicate
samples with ferumoxides (Endorem®)-protamine sulphate complexes at
doses ranging from 0 - 250 μg iron/ml. After incubation for 24 hours, cell
viability was assessed using a trypan blue exclusion assay. Subsequently,
metabolic cell activity was quantiﬁed using the AlamarBlue® assay up to
seven days after labeling. Chondrogenic capacity of hBMSCs labeled with
100 μg/ml SPIO was evaluated using thionine staining and collagen type II
immunohistochemistry.
Intra-articular imaging: SPIO-labeled hBMSCs (100,000 to 5,000,000 cells)
were injected ex vivo in pig knees, to mimic a clinically relevant sized
model. Furthermore, SPIO-labeled cells (10,000 - 1,000,000 per 75 μl) were
seeded in cartilage defects in vitro. Scanning was performed on a clinical
3.0 T MRI scanner.
SPIO re-uptake: To study possible SPIO re-uptake by synovial cells, viable
and dead GFP-SPIO double-labeled chondrocytes were seeded on human
synovium explants. After co-culturing for ﬁve days, samples were harvested
and analyzed using ﬂuorescence- and light microscopy.
Results: Safety: SPIO labeling resulted in labeling eﬃciencies of ± 95% and
did not impair cell viability or subsequent cell activity at any dose. SPIO-
labeled hBMSCs produced amounts of glycosaminoglycan and collagen type
II comparable to unlabeled control cells.
Intra-articular imaging: All SPIO-labeled cell dosages, both intra-articularly
injected and cells seeded in cartilage defects, were visualized by MRI (Fig.
1). Cell-dose dependent signal voids were observed, and cells could be
clearly differentiated from anatomical structures. SPIO-labeled cells seeded
in cartilage defects could be quantiﬁed using a T2* mapping MRI technique.
SPIO re-uptake: GFP+-SPIO+ cells, indicating originally seeded cells, were
seen in samples containing live cells. GFP--SPIO+ cells, indicating SPIO
re-uptake by synovial cells, were found in samples containing dead cells.
Conclusions: hBMSC labeling with SPIO particles is feasible, without
leading to negative effects on cell viability, subsequent metabolic cell ac-
tivity or chondrogenic differentiation. SPIO-labeled cells can be visualized
intra-articularly by MRI and quantiﬁed when seeded in a cartilage defect.
Although possible SPIO re-uptake by host cells has to be taken into account,
we showed promising results for the use of SPIO labeling for cell tracking
in clinical cartilage repair. This approach provides the extra advantage to
simultaneously track cells and evaluate cartilage repair in one MRI session.
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Purpose: Synovial membrane mesenchymal stem cells (MSCs) have been
demonstrated to be a good source of cells for the study of cartilage tissue
engineering. Multiple stem cells markers have been found by ﬂow cytom-
etry and immunoﬂuorescence in MSCs from human synovial membrane
pools. In this study we analyzed the chondrogenic potential of subpopula-
tions of MSCs derived from human synovial membranes enriched for CD73,
CD106 and CD271 markers.
Methods: Subpopulations of human synovial membrane MSCs enriched for
CD73, CD106 and CD271 markers were isolated using a cytometry sorter
and characterized by ﬂow cytometry for MSC markers. The expression
of Sox9, Nanog and Runx2 genes by these cells was measured by re-
verse transcriptase-polymerase chain reaction. The chondrogenesis of each
subpopulation was assessed by culturing the cells in a deﬁned medium
to produce spontaneous spheroid formation and differentiation towards
chondrocyte-like cells. The examination of the spheroids by histological
and immunohistochemical analyses for collagen type II (COL2), aggrecan,
collagen type I (COL1), metalloprotease 13 (MMP13) and collagen type
X (COLX) levels were performed to assess their chondrogenesis capacity.
The adipogenesis and osteogenesis potential of each subpopulation was
determined using commercial media; the resulting cells were stained with
oil red O or red alizarin to test the degree of differentiation.
Results: The subpopulations had different proﬁles of cells positive for
the MSC markers CD44, CD69, CD73, CD90 and CD105 and showed dif-
ferent expression levels of the genes Sox9, Nanog, Runx2 involved in
chondrogenesis, undifferentiation and osteoblastogenesis, respectively. Im-
munohistochemical analysis demonstrated that COL1, COL2, COLX, MMP13
and aggrecan were expressed in the spheroids as soon as 14 days of culture.
The CD271+ subpopulation expressed the highest levels of COL2 staining
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compared to the other subpopulations. CD105 and Runx2 were shown by
immunohistochemistry and genetic analysis to have signiﬁcantly higher
expression CD271+ subpopulation than the other subpopulations.
Conclusions: Spheroids formed from CD271-enriched and CD73-enriched
MSCs from normal human synovial membranes mimic the native cartilage
extracellular matrix more closely than CD106+ MSCs and are possible
candidates for use in cartilage tissue engineering. Both cell types have
potential for promoting the differentiation of MSCs into chondrocytes,
presenting new possibilities for achieving intrinsic cartilage repair.
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Purpose: Therapeutic gene transfer might be a means to enhance the
reparative activities in articular cartilage lesions. We previously reported
that recombinant adeno-associated viral (rAAV) vectors are capable of de-
livering transgene sequences to articular cartilage defects in experimental
models over extended periods of time. In the present study, we tested the
hypothesis that eﬃcient and sustained overexpression of IGF-I via direct
application of rAAV enhances the healing of osteochondral defects created
in the knee joints of rabbits in vivo.
Methods: rAAV were packaged, puriﬁed by dialysis, and titrated by real-
time PCR. rAAV-lacZ carries the E. coli beta-galactosidase (β-gal) marker
gene (lacZ) controlled by the CMV-IE promoter/enhancer. A human insulin-
like growth factor-I (hIGF-I) cDNA was cloned in rAAV-lacZ instead of lacZ
to produce rAAV-hIGF-I. Two osteochondral defects (3.2-mm in diameter)
were created in each patellar groove of Chinchilla bastard rabbits (n = 8).
Each animal received alternatively 10 μ l rAAV-hIGF-I per defect on one
knee (IGF-I-treated defects) and 10 μl rAAV-lacZ per defect on the con-
tralateral knee (control defects). At 3 weeks post operation, cartilage repair
was assessed based on safranin O/hematoxylin eosin-stained sections using
a histological grading system. A total of 145 paraﬃn-embedded sections
(5 μm) were scored independently by two individuals that were blinded
with respect to the treatment. Points for each category and total score
were compared between the groups using a mixed general linear model
with repeated-measures analysis of variance. Indirect immunohistochemi-
cal staining was also performed to detect β-gal, hIGF-I, and type-II collagen.
The DNA, proteoglycan, and type-II collagen contents of the repair tissue
within the defects were measured using Hoechst 33258, by binding to
DMMB dye, and by ELISA, respectively. Data are expressed as mean ± SD.
The t-test and the Mann-Whitney Rank Sum Test were employed where
appropriate.
Figure 1. Safranin O staining (A, B) and type-II collagen immunoreactivity (C, D) in osteo-
chondral defects 3 weeks after vector application (A, C: rAAV-lacZ; B, D: rAAV-hIGF-I).
Magniﬁcation ×2.
Results: Following direct application of the vectors in vivo, there were no
signs of synovitis, adhesions, or adverse reactions, and no macroscopically
descriptive differences between the IGF-I-treated and control knees. β-gal
activity was restricted to the control defects, whereas IGF-I expression
was present only in the IGF-I-treated defects. After 3 weeks, enhanced
tissue healing was observed in the IGF-I-treated defects (Fig. 1). Improved
individual parameter scores were observed for defect ﬁlling, integration,
matrix staining, cellular morphology, defect and surface architecture, new
subchondral bone formation (all P<0.001) and tidemark (P<0.01) of the
IGF-I-treated defects, with also a signiﬁcantly improved total score vis a
vis control treatment (P<0.001). Immunoreactivity to type-II collagen was
more intense and regular in the IGF-I-treated defects (Fig. 1). Biochemical
analyses performed on the repair tissue from the defects revealed that
treatment with rAAV-hIGF-I promoted a signiﬁcant increase in the DNA
(3.2-fold; P<0.001), proteoglycan (1.2-fold; P = 0.01), and type-II collagen
contents (2.8-fold; P<0.001).
Conclusions: The data indicate that IGF-I can be overexpressed in osteo-
chondral defects in vivo via rAAV transduction, leading to the production
of a recombinant IGF-I factor that is capable of signiﬁcantly improving the
healing of the defects, stimulating both cell proliferation and extracellular
matrix synthesis. The results suggest that therapeutic rAAV may have value
in enhancing cartilage repair by application to sites of cartilage damage.
Further studies are required to evaluate the long-term properties of the
repair tissue.
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Purpose: Cartilage defects arise primarily due to traumatic or degenerative
changes and in the medium to long-term often result in osteoarthritis and
total joint replacement. One aim of modern orthopaedics is to avoid TJR.
For traumatic and small focal degenerative cartilage defects, in the recent
years promising treatment options like lavage, abrasion, osteochondral au-
tograft transfer, microfracture, cell-free implants, autologous chondrocyte
transplantation and matrix assisted ACT have been developed. However,
these therapies cannot completely arrest OA progression and currently are
not applied for the treatment of large OA defects. This is partly due to
a lack of knowledge regarding the cellular and molecular characteristics
of OA chondrocytes. The extracellular matrix is the functional element in
cartilage and its degradation is central in the pathogenetic process in OA.
In addition, new formation of ECM is crucial in OA chondrocyte based
therapies. Therefore, the aim of our study was to provide a more complete
picture of the cellular and molecular alterations in OA cartilage and to
analyze cartilage formation by OA-chondrocytes.
Methods: Human articular cartilage biopsies were collected from OA
patients as well as healthy normal donors. RNA was isolated from the
biopsies and subjected to genome-wide microarray analysis. Important
results were veriﬁed using qPCR and immunohistochemistry. Furthermore,
chondrocytes were harvested from such biopsies applying protocols used
for ACT. Their chondrogenic potential was studied in high-density pel-
let and hyaff-11 cultures by proteoglycan and collagen type II staining.
Moreover, chondrocytes cultured in monolayer and hyaff-11 scaffolds were
subjected to microarray gene expression proﬁling. Again, expression data
were veriﬁed by qPCR.
Results: We detected genes already associated with normal cartilage and
alterations in OA cartilage but also detected new candidates not previously
associated with this disease. Here, the expression of genes coding for colla-
gens (COL8A2, COL13-15A1) or related to bone formation (CLEC3B, CDH11,
GPNMB, CLEC3A, CHST11, MSX1-2) was signiﬁcantly higher in native OA
cartilage than in native ND cartilage. In 3D hyaff-11 cultures, chondrocytes
from ND and OA donors secreted comparable amounts of ECM components
like proteoglycans and collagen type II. Expression of cartilage marker
genes (ACAN, COL2A1, COMP, SOX9) and genes involved in matrix syn-
thesis (BGN, COL9A2, COL11A1) was highly induced in 3D ND and OA
